Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Syros Pharmaceuticals Inc SYRS

Healthcare Biotechnology
Syros Pharmaceuticals, Inc. is not engaged in any business activities. The Company is actively engaged in the voluntary delisting process. The Company was previously engaged in developing new standards of care for the frontline treatment of patients with hematologic malignancies.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (GREY:SYRS)

Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration

Business Wire February 28, 2025

Syros Stock - Investors of Syros Pharmaceuticals Encouraged to Contact Kehoe Law Firm, P.C. - SYRS

Newsfile November 13, 2024

Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression

Business Wire November 12, 2024

The Schall Law Firm Invites Investors To Join An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Related Infractions

ACCESS Newswire November 4, 2024

Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Shareholders With Losses Are Encouraged To Contact The Schall Law Firm

ACCESS Newswire November 3, 2024

The Schall Law Firm Urges Investors To Join An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Law Violations

ACCESS Newswire November 2, 2024

Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Affected Shareholders Are Encouraged To Contact The Schall Law Firm

ACCESS Newswire October 31, 2024

Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update

Business Wire October 31, 2024

The Schall Law Firm Urges Investor Participation In An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Law Violations

ACCESS Newswire October 30, 2024
View More News ››

Opinion & Analysis (GREY:SYRS)

Syros Pharma Teams Up with Global Blood Therapeutics to Fight Sickle Cell Disease

Streetwise Reports December 19, 2019

2017 Small-Cap biotech watchlist update: holding steady in a volatile market

The Life Sciences Report April 21, 2017

2017 Small-Cap Biotech Watchlist: takeaways for investors

The Life Sciences Report January 19, 2017
View More Opinion ››

Bullboard Posts (GREY:SYRS)

Syros Pharmaceuticals (SYRS): A Biopharmaceutical Firm Commi

https://beyondspx.com/article/syros-pharmaceuticals-syrs-a-biopharmaceutical-firm-committed-to-advancing-hematologic-malignancy...
MikeTester - January 22, 2025

Syros (NASDAQ:SYRS) Poised for Potential Breakthrough in Hem

http://beyondspx.com/2024/07/31/syros-nasdaqsyrs-poised-for-potential-breakthrough-in-hematologic-malignancies/
MikeTester - August 2, 2024
View more Bullboard ››

dynaCERT Inc.

dynaCERT Inc.

dynaCERT Inc. is a Canada-based company, which manufactures and distributes carbon emission reduction technology along with ...
View More »